← Leaderboards
Jeremy A Elser
Ship Of Theseus, Llc
$3,164,380
Attributed
$3,364,249
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2021–25$2.5M$1.9M$1.3M$625K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,364,249 · 5
By mechanism
R44$1,770,171 · 1
R61$457,450 · 1
R33$443,800 · 1
R41$399,739 · 1
R43$293,089 · 1
Top collaborators
- Saar Gill1 shared
Others in their field
Other Emerging Leaders on “Resistance”
- John Damon Chodera · Sloan-Kettering Inst Can Research$56,843,703
- Urs Ochsner · Crestone, Inc.$40,390,611
- Ryan Cirz · Revagenix, Inc.$40,209,479
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Michael Dignam · National Institute Of Allergy And Infectious Diseases$30,845,607
- Daniel Pevear · Venatorx Pharmaceuticals, Inc.$24,789,028
Research focus
ResistanceHematopoieticPeripheral BloodProteinsTransplantationHematopoietic Stem Cell ExpansionIn VivoPeptidesPost-TransplantProliferatingSafetyTranscription FactorTransplant RecipientsCellsHematopoietic Stem Cell TransplantationIn VitroNeutropeniaPatient-Focused OutcomesCd34 GeneHematopoietic Stem CellsClinical TrialsFemaleHigh RiskCell Transplantation
Grant awards (6)
Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant$1,770,171
R44 · FY2025 · HL · contact PI
Preclinical development of a tandem CART / HSC transplantation platform for hematologic malignancies$399,739
R41 · FY2025 · CA · contact PI
Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant$213,500
R33 · FY2024 · HL · contact PI
Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant$230,300
R33 · FY2023 · HL · contact PI
Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant$457,450
R61 · FY2022 · HL · contact PI
Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant$293,089
R43 · FY2021 · HL · contact PI